Welcome to our dedicated page for Livanova Plc SEC filings (Ticker: LIVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LivaNova PLC filings document the regulatory disclosures of an England and Wales public limited company with ordinary shares listed on Nasdaq under LIVN. Its Form 8-K reports primarily cover operating and financial results, earnings releases, business update calls, material events, and governance changes involving senior officers.
Proxy materials describe annual general meeting procedures, shareholder voting matters, director and governance proposals, and the company’s ordinary share structure. The filings also provide formal records for capital-structure disclosures and corporate governance matters relevant to LivaNova’s medical technology operations in neurological and cardiac conditions.
LivaNova PLC reported stronger Q3 2025 results. Net revenue rose to $357.8 million from $318.1 million, with operating income of $54.0 million and net income of $26.8 million ($0.49 diluted). For the first nine months, the company posted a net loss of $273.4 million, primarily driven by the $363.8 million SNIA environmental liability expense booked earlier in the year.
Cash and cash equivalents were $646.1 million, aided by operating cash flow of $171.9 million year-to-date. LivaNova repaid $200 million on its Term Facilities in May, reducing long-term debt to $349.0 million. The company recorded a current liability of $394.6 million (€336.3 million) related to the SNIA matter, reflecting its best estimate including costs, fees, interest, and taxes.
On the cybersecurity incident disclosed in 2023, cumulative direct costs totaled $13.1 million through September 30, 2025, and insurance reimbursements received totaled $9.6 million. Ordinary shares outstanding were 54,605,527 as of October 29, 2025.
LivaNova PLC furnished an 8-K announcing financial results for the quarter ended September 30, 2025. The company will host a business update conference call and webcast on November 5, 2025, at 1 p.m. London time (8 a.m. Eastern Time), accessible via its events page.
The related press release is attached as Exhibit 99.1 and, under Item 2.02, is being furnished and not deemed filed under the Exchange Act.
LivaNova PLC (LIVN) director Donald Zurbay was granted 2,560 Restricted Stock Units (RSUs) on September 15, 2025. Each RSU converts to one ordinary share under the LivaNova PLC 2025 Director Incentive Award Plan. The grant carries vesting and forfeiture restrictions that are scheduled to lapse on June 15, 2026, subject to continued service and the award agreement. The reported RSUs have a $0 per-unit reported grant price on the Form 4 and are shown as directly beneficially owned following the award. The Form 4 was signed on behalf of the reporting person by an Attorney-in-Fact on September 17, 2025.
LivaNova PLC (LIVN) reporting person Franco Poletti had 643 restricted stock units (RSUs) vest and be settled into ordinary shares on September 15, 2025. Of those vested shares, 277 shares were withheld to satisfy tax withholding at an effective price shown as $55.43 per share, leaving 643 net shares credited from the RSU settlement in the transaction record. Following the reported transactions the form shows 8,576 shares beneficially owned by the reporting person, 8,299 shares after the withholding line, and 219 shares held indirectly by spouse. The RSUs were granted September 15, 2024 under the company’s 2022 Incentive Award Plan and vest in equal annual installments over four years, with the first vesting on September 15, 2025.
LivaNova PLC (LIVN) Form 3 filed for Donald Zurbay records that the reporting person is a Director and that the event date was 09/03/2025. The filing shows 0 ordinary shares beneficially owned directly. The form is signed by an attorney-in-fact and includes Exhibit 24 - Power of Attorney.
LivaNova PLC reported that its Board of Directors appointed Donald Zurbay as a director and member of the Audit and Compliance Committee, effective September 4, 2025. He brings more than 20 years of leadership experience in healthcare, including serving as President, Chief Executive Officer and director of Patterson Companies, Inc. from October 2022 to May 2025, and previously as its Chief Financial Officer from June 2018 to October 2022. He also held senior finance roles at St. Jude Medical, Inc., including Chief Financial Officer.
As a non-executive director, Zurbay will be compensated under LivaNova’s Remuneration Policy, including an annual board retainer of $70,000, an Audit and Compliance Committee member fee of $15,000, and an annual service-based restricted stock award valued at $185,000, all prorated until the 2026 Annual General Meeting. The company states there is no special arrangement leading to his selection and no related-party transactions requiring disclosure.
LivaNova director Francesco Bianchi sold 1,500 ordinary shares on 08/25/2025 at a reported price of $56.50 per share. After the sale he beneficially owned 9,028 ordinary shares, reported as direct ownership. The Form 4 was signed on behalf of the reporting person by Sarah K. Mohr, Attorney-in-Fact, on 08/27/2025. The filing discloses the transaction code S (sale) and provides the reporter's London address; no derivative transactions or amendments are reported.
LivaNova PLC (LIVN) submitted a Form 144 notice reporting a proposed sale of 1,500 ordinary shares through Merrill Lynch with an aggregate market value of $84,750. The shares were acquired on 06/29/2021 upon vesting of a restricted stock unit award granted under the issuer's equity compensation plan. The filer indicates the approximate date of sale as 08/25/2025 and the intended exchange is NASDAQ. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer and references Rule 144 and Rule 10b5-1 trading plan considerations.
LivaNova PLC (LIVN) Q2-25 10-Q highlights:
- Net revenue rose 10.6% YoY to $352.5 m; six-month revenue up 9.1% to $669.4 m.
- Gross margin held steady at 67.8%; operating income jumped 34.9% to $54.2 m on disciplined SG&A (+10.1%) and R&D spend (-7.9%).
- GAAP EPS improved to $0.50 versus $0.30; diluted share count 54.7 m.
- Six-month results swung to a $300.2 m loss after booking a $362.1 m SNIA environmental charge.
- Cash climbed to $593.6 m (-$130 m q-o-q after releasing $294.7 m restricted cash); total debt reduced 31% to $430.6 m following a $200 m early term-loan repayment.
- SNIA litigation reserve now $392.3 m; €270 m surety bond in place pending appeal. Cyber-incident costs reached $13 m, with $9.6 m insurance recovery to date.
- Liquidity: $225 m revolver undrawn; operating cash flow +63% YoY to $86.9 m H1-25.
- No covenant breaches; capped-call and embedded derivatives re-measured, neutral P&L effect.
Management reaffirmed focus on core Cardiopulmonary & Neuromodulation segments and continues restructuring begun 2024. Litigation and environmental exposures remain the key overhang despite solid operating momentum and deleveraging.